Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28337804 | 0.83 | KDM1A (0.31) | — | |
| SCHEMBL14248785 | 0.82 | CES2 (0.39) | MEN1KMT2A | |
| SCHEMBL3836665 | 0.80 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL16652774 | 0.76 | KDM1A (0.31) | — | |
| SCHEMBL29396883 | 0.76 | KDM1A (0.31) | — | |
| SCHEMBL24105705 | 0.75 | HTT (0.34) | MEN1KMT2A | |
| SCHEMBL14956230 | 0.73 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL10669681 | 0.72 | CES2 (0.40) | MEN1KMT2A | |
| SCHEMBL30282313 | 0.70 | MAPT (0.38) | MEN1KMT2A | |
| SCHEMBL12678823 | 0.68 | NQO2 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102036988-B | Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo [1,2-a ] pyridines, their preparation and their therapeutic use | SANOFI AVENTIS | 2013-08-07 | — | — | CN | disclosed |
| EP-2262803-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-10-17 | — | — | EP | disclosed |
| US-8148370-B2 | Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| CN-102036988-A | Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo [1,2-a ] pyridines, their preparation and their therapeutic use | SANOFI AVENTIS | 2011-04-27 | — | — | CN | disclosed |
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2262803-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009144391-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | MEN1 3370/4885KMT2A 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.